Base de dados : MEDLINE
Pesquisa : G09.188.114 [Categoria DeCS]
Referências encontradas : 5306 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 531 ir para página                         

  1 / 5306 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28923282
[Au] Autor:Pereira N; Patel HH; Stone LD; Christos PJ; Elias RT; Spandorfer SD; Rosenwaks Z
[Ad] Endereço:The Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine, Weill Cornell Medical College, New York, New York. Electronic address: nip9060@med.cornell.edu.
[Ti] Título:Association between ABO blood type and live-birth outcomes in single-embryo transfer cycles.
[So] Source:Fertil Steril;108(5):791-797, 2017 Nov.
[Is] ISSN:1556-5653
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To investigate the association between ABO blood type and live-birth outcomes in patients undergoing IVF with day 5 single-embryo transfer (SET). DESIGN: Retrospective cohort study. SETTING: University-affiliated center. PATIENT(S): Normal responders, <40 years old, undergoing their first IVF cycle with fresh SET. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Live-birth rate was the primary outcome. Secondary outcomes were birth weight and gestational age at delivery. Univariate and multivariable logistic regression was used to examine the association between blood type and live birth, while controlling for confounders. Odds ratios (OR) with 95% confidence intervals (CI) for live birth were estimated. RESULT(S): A total of 2,329 patients were included. The mean age of the study cohort was 34.6 ± 4.78 years. The distribution of blood types was as follows: A = 897 (38.5%); B = 397 (17.0%); AB = 120 (5.2%); and, O = 1,915 (39.3%) patients. There was no difference in the baseline demographics, ovarian stimulation, or embryo quality parameters between the blood types. The unadjusted ORs for live birth when comparing blood type A (referent) with blood types B, AB, and O were 0.96 (95% CI, 0.6-1.7), 0.72 (95% CI, 0.4-1.2), and 0.96 (95% CI. 0.6-1.7), respectively. The adjusted ORs for live birth remained not significant when comparing blood type A to blood types B, AB, and O individually. No difference in birth weight or gestational age at delivery was noted among the four blood types. CONCLUSION(S): Our findings suggest that ABO blood type is not associated with live-birth rate, birth weight, or gestational age at delivery in patients undergoing IVF with day 5 SET.
[Mh] Termos MeSH primário: Sistema do Grupo Sanguíneo ABO
Blastocisto
Incompatibilidade de Grupos Sanguíneos/complicações
Fertilização In Vitro
Infertilidade/terapia
Transferência de Embrião Único
[Mh] Termos MeSH secundário: Adulto
Peso ao Nascer
Incompatibilidade de Grupos Sanguíneos/diagnóstico
Implantação do Embrião
Feminino
Fertilidade
Fertilização In Vitro/efeitos adversos
Idade Gestacional
Seres Humanos
Infertilidade/diagnóstico
Infertilidade/fisiopatologia
Nascimento Vivo
Modelos Logísticos
Análise Multivariada
Razão de Chances
Gravidez
Complicações na Gravidez/etiologia
Taxa de Gravidez
Estudos Retrospectivos
Fatores de Risco
Transferência de Embrião Único/efeitos adversos
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (ABO Blood-Group System)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171113
[Lr] Data última revisão:
171113
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170920
[St] Status:MEDLINE


  2 / 5306 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28840943
[Au] Autor:Zeller MP; Barty R; Aandahl A; Apelseth TO; Callum J; Dunbar NM; Elahie A; Garritsen H; Hancock H; Kutner JM; Manukian B; Mizuta S; Okuda M; Pagano MB; Poglód R; Rushford K; Selleng K; Sørensen CH; Sprogøe U; Staves J; Weiland T; Wendel S; Wood EM; van de Watering L; van Wordragen-Vlaswinkel M; Ziman A; Jan Zwaginga J; Murphy MF; Heddle NM; Yazer MH; Biomedical Excellence for Safer Transfusion (BEST) Collaborative
[Ad] Endereço:McMaster Centre for Transfusion Research, McMaster University, Hamilton, Ontario, Canada.
[Ti] Título:An international investigation into O red blood cell unit administration in hospitals: the GRoup O Utilization Patterns (GROUP) study.
[So] Source:Transfusion;57(10):2329-2337, 2017 Oct.
[Is] ISSN:1537-2995
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Transfusion of group O blood to non-O recipients, or transfusion of D- blood to D+ recipients, can result in shortages of group O or D- blood, respectively. This study investigated RBC utilization patterns at hospitals around the world and explored the context and policies that guide ABO blood group and D type selection practices. STUDY DESIGN AND METHODS: This was a retrospective study on transfusion data from the 2013 calendar year. This study included a survey component that asked about hospital RBC selection and transfusion practices and a data collection component where participants submitted information on RBC unit disposition including blood group and D type of unit and recipient. Units administered to recipients of unknown ABO or D group were excluded. RESULTS: Thirty-eight hospitals in 11 countries responded to the survey, 30 of which provided specific RBC unit disposition data. Overall, 11.1% (21,235/191,397) of group O units were transfused to non-O recipients; 22.6% (8777/38,911) of group O D- RBC units were transfused to O D+ recipients, and 43.2% (16,800/38,911) of group O D- RBC units were transfused to recipients that were not group O D-. Disposition of units and hospital transfusion policy varied within and across hospitals of different sizes, with transfusion of group O D- units to non-group O D- patients ranging from 0% to 33%. CONCLUSION: A significant proportion of group O and D- RBC units were transfused to compatible, nonidentical recipients, although the frequency of this practice varied across sites.
[Mh] Termos MeSH primário: Transfusão de Eritrócitos/utilização
Eritrócitos/imunologia
[Mh] Termos MeSH secundário: Sistema do Grupo Sanguíneo ABO/imunologia
Incompatibilidade de Grupos Sanguíneos
Hospitais
Seres Humanos
Estudos Retrospectivos
Sistema do Grupo Sanguíneo Rh-Hr/imunologia
Inquéritos e Questionários
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (ABO Blood-Group System); 0 (Rh-Hr Blood-Group System)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171023
[Lr] Data última revisão:
171023
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170826
[St] Status:MEDLINE
[do] DOI:10.1111/trf.14255


  3 / 5306 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28815621
[Au] Autor:Lodermeier MA; Byrne KM; Flegel WA
[Ad] Endereço:Department of Transfusion Medicine, National Institutes of Health Clinical Center, National Institutes of Health, Bethesda, Maryland.
[Ti] Título:Red blood cell sedimentation of Apheresis Granulocytes.
[So] Source:Transfusion;57(10):2551-2552, 2017 Oct.
[Is] ISSN:1537-2995
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Sedimentation of Apheresis Granulocyte components removes red blood cells. It is used to increase the blood donor pool when blood group-compatible donors cannot be recruited for a patient because of a major ABO incompatibility or incompatible red blood cell antibodies in the recipient. Because granulocytes have little ABO and few other red blood cell antigens on their membrane, such incompatibility lies mostly with the contaminating red blood cells. Video Clip S1 shows the process of red blood cell sedimentation of an Apheresis Granulocyte component. This video was filmed with a single smart phone attached to a commercial tripod and was edited on a tablet computer with free software by an amateur videographer without prior video experience.
[Mh] Termos MeSH primário: Sedimentação Sanguínea
Granulócitos/citologia
Gravação em Vídeo/instrumentação
[Mh] Termos MeSH secundário: Remoção de Componentes Sanguíneos
Doadores de Sangue/provisão & distribuição
Incompatibilidade de Grupos Sanguíneos
Seres Humanos
Smartphone
Software
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171031
[Lr] Data última revisão:
171031
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170818
[St] Status:MEDLINE
[do] DOI:10.1111/trf.14251


  4 / 5306 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28719639
[Au] Autor:Cao H; Wu R; Han M; Caldwell PHY; Liu JP
[Ad] Endereço:College of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
[Ti] Título:Oral administration of Chinese herbal medicine during gestation period for preventing hemolytic disease of the newborn due to ABO incompatibility: A systematic review of randomized controlled trials.
[So] Source:PLoS One;12(7):e0180746, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: About 85.3% of hemolytic disease of the newborn (HDN) is caused by maternal-fetal ABO blood group incompatibility. However, there is currently no recommended "best" therapy for ABO incompatibility during pregnancy. OBJECTIVES: To systematically assess the safety and effectiveness of oral Chinese herbal medicine (CHM) for preventing HDN due to ABO incompatibility. METHODS: The protocol of this review was registered on the PROSPERO website (No. CRD42016038637).Six databases were searched from inception to April 2016. Randomized controlled trials (RCTs) of CHM for maternal-fetal ABO incompatibility were included. The primary outcome was incidence of HDN. The Cochrane risk of bias tool was used to assess the methodological quality of included trials. Risk ratios (RR) and mean differences with 95% confidence interval were used as effect measures. Meta-analyses using Revman 5.3 software were conducted if there were sufficient trials without obvious clinical or statistical heterogeneity available. RESULTS: Totally 28 RCTs involving3413 women were included in the review. The majority of the trials had unclear or high risk of bias. Our study found that the rate of HDN and the incidence of neonatal jaundice might be 70% lower in the herbal medicine group compared with the usual care group (RR from 0.25 to 0.30).After treatment with herbal medicine, women were twice as likely to have antibody titers lower than 1:64 compared with women who received usual care(RR from 2.15 to 3.14) and the umbilical cord blood bilirubin level in the herbal medicine group was 4umol/L lower than in those receiving usual care. There was no difference in Apgar scores or birthweights between the two groups. CONCLUSIONS: This review found very low-quality evidence that CHM prevented HDN caused by maternal-fetal ABO incompatibility. No firm conclusions can be drawn regarding the effectiveness or safety of CHM for this condition.
[Mh] Termos MeSH primário: Sistema do Grupo Sanguíneo ABO/imunologia
Incompatibilidade de Grupos Sanguíneos/imunologia
Medicamentos de Ervas Chinesas/administração & dosagem
Medicamentos de Ervas Chinesas/farmacologia
Hemólise/efeitos dos fármacos
Ensaios Clínicos Controlados Aleatórios como Assunto/métodos
[Mh] Termos MeSH secundário: Administração Oral
Feminino
Seres Humanos
Recém-Nascido
Gravidez
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (ABO Blood-Group System); 0 (Drugs, Chinese Herbal)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170927
[Lr] Data última revisão:
170927
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170719
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0180746


  5 / 5306 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28703860
[Au] Autor:Bailén R; Kwon M; Pérez-Corral AM; Pascual C; Buño I; Balsalobre P; Serrano D; Gayoso J; Díez-Martín JL; Anguita J
[Ad] Endereço:Hematology and Hemotherapy Department, Hospital General Universitario Gregorio Marañón.
[Ti] Título:Transient hemolysis due to anti-D and anti-A produced by engrafted donor's lymphocytes after allogeneic unmanipulated haploidentical hematopoietic stem cell transplantation.
[So] Source:Transfusion;57(10):2355-2358, 2017 Oct.
[Is] ISSN:1537-2995
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Development of de novo alloantibodies against recipient's red blood cell (RBC) antigens by engrafted donor's lymphocytes is a known phenomenon in the setting of allogeneic hematopoietic stem cell transplantation (HSCT). This situation is usually clinically insignificant. We report a case of early clinically relevant hemolytic anemia in a blood group A D+ patient, due to a limited production of anti-D and anti-A produced by nonpreviously sensitized newly engrafted donor's immune system. CASE REPORT: A 31-year-old Caucasian woman, blood group A , D+, with Hodgkin's lymphoma, received an unmanipulated haploidentical allogeneic peripheral blood HSCT after a nonmyeloablative conditioning regimen. Donor blood group was A B, D-. The patient had an uneventful course until Day +34, when she developed clinically significant hemolytic anemia with a positive direct antiglobulin test. Anti-D and anti-A produced by the donor-engrafted lymphocytes were detected both in serum and in eluate. The hemolysis produced an accelerated group change, turning the patient's ABO group into A B 2 weeks after the detection of the alloantibodies. As the residual patient's RBCs progressively disappeared, anti-D and anti-A production decreased and were not detected in serum by Day +41. CONCLUSION: This case illustrates that de novo alloantibody production against ABO and D antigens by the newly engrafted donor's lymphocytes can occasionally cause clinically significant anemia. To our knowledge, this is the first case reported of clinically significant hemolytic anemia due to a transient anti-D anti-A alloimmunization after T-cell-repleted haploidentical HSCT.
[Mh] Termos MeSH primário: Anemia Hemolítica/etiologia
Transplante de Células-Tronco Hematopoéticas/efeitos adversos
Isoanticorpos/biossíntese
Linfócitos/imunologia
Imunoglobulina rho(D)/biossíntese
[Mh] Termos MeSH secundário: Sistema do Grupo Sanguíneo ABO/imunologia
Adulto
Incompatibilidade de Grupos Sanguíneos
Feminino
Sobrevivência de Enxerto
Seres Humanos
Isoanticorpos/sangue
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (ABO Blood-Group System); 0 (Isoantibodies); 0 (RHO(D) antibody); 0 (Rho(D) Immune Globulin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171023
[Lr] Data última revisão:
171023
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170714
[St] Status:MEDLINE
[do] DOI:10.1111/trf.14232


  6 / 5306 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28653325
[Au] Autor:Gehrie EA; Ness PM; Bloch EM; Kacker S; Tobian AAR
[Ad] Endereço:Department of Pathology, Johns Hopkins University, Baltimore, Maryland.
[Ti] Título:Medical and economic implications of strategies to prevent alloimmunization in sickle cell disease.
[So] Source:Transfusion;57(9):2267-2276, 2017 Sep.
[Is] ISSN:1537-2995
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The pathogenesis of alloimmunization is not well understood, and initiatives that aim to reduce the incidence of alloimmunization are generally expensive and either ineffective or unproven. In this review, we summarize the current medical literature regarding alloimmunization in the sickle cell disease (SCD) population, with a special focus on the financial implications of different approaches to prevent alloimmunization. STUDY DESIGN AND METHODS: A review of EMBASE and MEDLINE data from January 2006 through January 2016 was conducted to identify articles relating to complications of SCD. The search was specifically designed to capture articles that evaluated the costs of various strategies to prevent alloimmunization and its sequelae. RESULTS: Currently, there is no proven, inexpensive way to prevent alloimmunization among individuals with SCD. Serologic matching programs are not uniformly successful in preventing alloimmunization, particularly to Rh antigens, because of the high frequency of variant Rh alleles in the SCD population. A genotypic matching program could offer some cost savings compared to a serologic matching program, but the efficacy of gene matching for the prevention of alloimmunization is largely unproven, and large-scale implementation could be expensive. CONCLUSIONS: Future reductions in the costs associated with genotype matching could make a large-scale program economically feasible. Novel techniques to identify patients at highest risk for alloimmunization could improve the cost effectiveness of antigen matching programs. A clinical trial comparing the efficacy of serologic matching to genotype matching would be informative.
[Mh] Termos MeSH primário: Anemia Falciforme/terapia
Incompatibilidade de Grupos Sanguíneos/prevenção & controle
Tipagem e Reações Cruzadas Sanguíneas/métodos
Transfusão de Sangue/métodos
[Mh] Termos MeSH secundário: Anemia Falciforme/imunologia
Incompatibilidade de Grupos Sanguíneos/economia
Tipagem e Reações Cruzadas Sanguíneas/economia
Transfusão de Sangue/economia
Análise Custo-Benefício
Genótipo
Seres Humanos
Reação Transfusional
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171122
[Lr] Data última revisão:
171122
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170628
[St] Status:MEDLINE
[do] DOI:10.1111/trf.14212


  7 / 5306 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28439910
[Au] Autor:Canaani J; Savani BN; Labopin M; Michallet M; Craddock C; Socié G; Volin L; Maertens JA; Crawley C; Blaise D; Ljungman PT; Cornelissen J; Russell N; Baron F; Gorin N; Esteve J; Ciceri F; Schmid C; Giebel S; Mohty M; Nagler A
[Ad] Endereço:Hematology Division, Chaim Sheba Medical Center, Tel-Hashomer, Tel Aviv University, Israel.
[Ti] Título:ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: A report from the acute leukemia working party of the EBMT.
[So] Source:Am J Hematol;92(8):789-796, 2017 Aug.
[Is] ISSN:1096-8652
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:ABO incompatibility is commonly observed in stem cell transplantation and its impact in this setting has been extensively investigated. HLA-mismatched unrelated donors (MMURD) are often used as an alternative stem cell source but are associated with increased transplant related complications. Whether ABO incompatibility affects outcome in MMURD transplantation for acute myeloid leukemia (AML) patients is unknown. We evaluated 1,013 AML patients who underwent MMURD transplantation between 2005 and 2014. Engraftment rates were comparable between ABO matched and mismatched patients, as were relapse incidence [34%; 95% confidence interval (CI), 28-39; for ABO matched vs. 36%; 95% CI, 32-40; for ABO mismatched; P = .32], and nonrelapse mortality (28%; 95% CI, 23-33; for ABO matched vs. 25%; 95% CI, 21-29; for ABO mismatched; P = .2). Three year survival was 40% for ABO matched and 43% for ABO mismatched patients (P = .35), Leukemia free survival rates were also comparable between groups (37%; 95% CI, 32-43; for ABO matched vs. 38%; 95% CI, 33-42; for ABO mismatched; P = .87). Incidence of grade II-IV acute graft versus host disease was marginally lower in patients with major ABO mismatching (Hazard ratio of 0.7, 95% CI, 0.5-1; P = .049]. ABO incompatibility probably has no significant clinical implications in MMURD transplantation.
[Mh] Termos MeSH primário: Incompatibilidade de Grupos Sanguíneos
Transplante de Células-Tronco Hematopoéticas
Leucemia Mieloide Aguda/epidemiologia
Leucemia Mieloide Aguda/terapia
Doadores não Relacionados
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Incompatibilidade de Grupos Sanguíneos/genética
Incompatibilidade de Grupos Sanguíneos/imunologia
Feminino
Sobrevivência de Enxerto
Doença Enxerto-Hospedeiro/diagnóstico
Doença Enxerto-Hospedeiro/etiologia
Antígenos HLA/genética
Antígenos HLA/imunologia
Transplante de Células-Tronco Hematopoéticas/efeitos adversos
Transplante de Células-Tronco Hematopoéticas/métodos
Seres Humanos
Leucemia Mieloide Aguda/genética
Leucemia Mieloide Aguda/imunologia
Masculino
Meia-Idade
Estudos Retrospectivos
Análise de Sobrevida
Condicionamento Pré-Transplante
Transplante Homólogo
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (HLA Antigens)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170728
[Lr] Data última revisão:
170728
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170426
[St] Status:MEDLINE
[do] DOI:10.1002/ajh.24771


  8 / 5306 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28425753
[Au] Autor:Dara RC; Tiwari AK; Arora D; Mitra S; Aggarwal G; Acharya DP; Bhardwaj G
[Ad] Endereço:Attending Consultant.
[Ti] Título:Applications of selected cells in immunohematology in a developing country: case studies.
[So] Source:Immunohematology;33(1):27-35, 2017 Jan.
[Is] ISSN:0894-203X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:CONCLUSIONS: When an antibody is detected, its specificity should be determined and its likely clinical significance should be assessed. When one antibody has been identified, it becomes necessary to confirm the presence of additional significant antibodies to ensure that compatible blood is provided to the patient. To perform this confirmation, specific reagent red blood cells (RBCs) are selected; these are called selected cells. Though the most common use of selected cells is for antibody confirmation, they can also be used for several other immunohematologic applications. In a developing country like India, the performance of antibody screening for unexpected antibodies on a routine basis is a comparatively new phenomenon, and those laboratories performing advanced immunohematologic testing would need to use selected cells to arrive at an accurate conclusion. This report defines selected cells and enumerates sources of these RBCs. Detailed immunohematologic applications are discussed with applicable case studies.
[Mh] Termos MeSH primário: Incompatibilidade de Grupos Sanguíneos/sangue
Tipagem e Reações Cruzadas Sanguíneas/métodos
Eritrócitos/imunologia
Isoanticorpos/análise
[Mh] Termos MeSH secundário: Adolescente
Adulto
Países em Desenvolvimento
Feminino
Seres Humanos
Índia
Isoanticorpos/imunologia
Masculino
Meia-Idade
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Isoantibodies)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170622
[Lr] Data última revisão:
170622
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170421
[St] Status:MEDLINE


  9 / 5306 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28425749
[Au] Autor:Joyce AJ; Quantock KM; Banh R; Liew YW
[Ad] Endereço:Blood Bank, Mater Health, Raymond Terrace, South Brisbane, 4101. Australia.
[Ti] Título:Hemolytic transfusion reaction attributable to anti-Dia.
[So] Source:Immunohematology;33(1):6-8, 2017 Jan.
[Is] ISSN:0894-203X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:CONCLUSIONS: In situations when a patient's antibody detection test is negative, many institutions have moved from an indirect antiglobulin test (IAT) crossmatch to an electronic crossmatch system. Here we report a case of an acute hemolytic transfusion reaction attributable to anti-Dia in a patient with a negative antibody detection test. A 22-year-old female patient with a diagnosis of ß thalassemia and sickle cell anemia commenced a routine exchange transfusion of 5 units of red blood cells (RBCs) in the apheresis unit as part of her regular treatment. When the patient started receiving the implicated unit, she reported back pain, chest pain, and a feeling of anxiety, suggestive of an acute transfusion reaction. The transfusion was ceased and an investigation of an adverse event was commenced. This case illustrates that the presence of antibodies to low-prevalence antigens remains a significant issue for transfusion-dependent individuals. To prevent other transfusion reactions by anti-Dia, the addition of Di(a+) cells to the reagent RBCs used for the antibody detection test along with IAT-crossmatching of donor units for all patients with sickle cell disease is recommended.
[Mh] Termos MeSH primário: Antígenos de Grupos Sanguíneos/imunologia
Incompatibilidade de Grupos Sanguíneos/etiologia
Reação Transfusional/etiologia
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
Adulto Jovem
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Blood Group Antigens)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170622
[Lr] Data última revisão:
170622
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170421
[St] Status:MEDLINE


  10 / 5306 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28402005
[Au] Autor:Allali S; Peyrard T; Amiranoff D; Cohen JF; Chalumeau M; Brousse V; de Montalembert M
[Ad] Endereço:Department of Paediatrics, Necker Hospital for Sick Children, Paris Descartes University, Paris, France.
[Ti] Título:Prevalence and risk factors for red blood cell alloimmunization in 175 children with sickle cell disease in a French university hospital reference centre.
[So] Source:Br J Haematol;177(4):641-647, 2017 May.
[Is] ISSN:1365-2141
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Patients with sickle cell disease (SCD) show a high prevalence of red blood cell (RBC) alloimmunization, but few studies have focused on children. We aimed to study the prevalence and risk factors of RBC alloimmunization in SCD children. We retrospectively analysed the medical and transfusion files for 245 SCD children hospitalized in our centre in 2014 and included 175 patients who had received at least one RBC unit in their lifetime. The main clinical and immuno-haematological characteristics of alloimmunized and non-alloimmunized patients were compared. The prevalence of alloimmunization was 13·7% [95% confidence interval (CI) (8·6-18·6)], and 7·4% [95% CI (3·5-11·3)] after excluding the probable irregular natural antibodies (anti-M, anti-Le , anti-Le , anti-Le ). Main risk factors for alloimmunization were increased number of RBC units received (median of 65 vs. 10 units per patient; P = 0·01) and the presence of one or more red cell autoantibodies (46·2% vs. 4·7%; P < 0·0001). The alloimmunization rate was higher for episodically transfused than chronically transfused patients (1·43 vs. 0·24/100 units received; P < 0·001). The presence of red cell autoantibodies appears to be a major risk factor for alloimmunization in SCD children and could justify specific transfusion guidelines.
[Mh] Termos MeSH primário: Anemia Falciforme/imunologia
Incompatibilidade de Grupos Sanguíneos/imunologia
Eritrócitos/imunologia
[Mh] Termos MeSH secundário: Adolescente
Criança
Transfusão de Eritrócitos/efeitos adversos
França
Homozigoto
Seres Humanos
Isoanticorpos/sangue
Prevalência
Estudos Retrospectivos
Fatores de Risco
Imunologia de Transplantes
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Isoantibodies)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170731
[Lr] Data última revisão:
170731
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170413
[St] Status:MEDLINE
[do] DOI:10.1111/bjh.14609



página 1 de 531 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde